Microtubule‐Targeting 7‐Deazahypoxanthines Derived from Marine Alkaloid Rigidins: Exploration of the N3 and N9 Positions and Interaction with Multidrug‐Resistance Proteins. (25th January 2019)
- Record Type:
- Journal Article
- Title:
- Microtubule‐Targeting 7‐Deazahypoxanthines Derived from Marine Alkaloid Rigidins: Exploration of the N3 and N9 Positions and Interaction with Multidrug‐Resistance Proteins. (25th January 2019)
- Main Title:
- Microtubule‐Targeting 7‐Deazahypoxanthines Derived from Marine Alkaloid Rigidins: Exploration of the N3 and N9 Positions and Interaction with Multidrug‐Resistance Proteins
- Authors:
- Dasari, Ramesh
Błauż, Andrzej
Medellin, Derek C.
Kassim, Roaa M.
Viera, Carlos
Santarosa, Maximo
van der Westhuyzen, Alet E.
van Otterlo, Willem A. L.
Olivas, Taryn
Yildiz, Tugba
Betancourt, Tania
Shuster, Charles B.
Rogelj, Snezna
Rychlik, Błażej
Hudnall, Todd
Frolova, Liliya V.
Kornienko, Alexander - Abstract:
- Abstract: Our laboratories have been investigating synthetic analogues of marine alkaloid rigidins that possess promising anticancer activities. These analogues, based on the 7‐deazahypoxanthine skeleton, are available in one‐ or two‐step synthetic sequences and exert cytotoxicity by disrupting microtubule dynamics in cancer cells. In the present work we extended the available structure–activity relationship (SAR) data to N3‐ and N9‐substituted derivatives. Although N3 substitution results in loss of activity, the N9‐substituted compounds retain nanomolar antiproliferative activities and the anti‐tubulin mode of action of the original unsubstituted compounds. Furthermore, our results also demonstrate that multidrug‐resistance (MDR) proteins do not confer resistance to both N9‐unsubstituted and ‐substituted compounds. It was found that sublines overexpressing ABCG2, ABCC1, and ABCB1 proteins are as responsive to the rigidin analogues as their parental cell lines. Thus, the study reported herein provides further impetus to investigate the rigidin‐inspired 7‐deazahypoxanthines as promising anticancer agents. Abstract : Expanding marine bounty : Analogues of marine alkaloid rigidins, based on the 7‐deazahypoxanthine skeleton, are available in one‐ or two‐step synthetic sequences and exert cytotoxicity by disrupting microtubule dynamics in cancer cells. In this work we extended the available SAR data to N3‐ and N9‐substituted derivatives. Furthermore, multidrug‐resistanceAbstract: Our laboratories have been investigating synthetic analogues of marine alkaloid rigidins that possess promising anticancer activities. These analogues, based on the 7‐deazahypoxanthine skeleton, are available in one‐ or two‐step synthetic sequences and exert cytotoxicity by disrupting microtubule dynamics in cancer cells. In the present work we extended the available structure–activity relationship (SAR) data to N3‐ and N9‐substituted derivatives. Although N3 substitution results in loss of activity, the N9‐substituted compounds retain nanomolar antiproliferative activities and the anti‐tubulin mode of action of the original unsubstituted compounds. Furthermore, our results also demonstrate that multidrug‐resistance (MDR) proteins do not confer resistance to both N9‐unsubstituted and ‐substituted compounds. It was found that sublines overexpressing ABCG2, ABCC1, and ABCB1 proteins are as responsive to the rigidin analogues as their parental cell lines. Thus, the study reported herein provides further impetus to investigate the rigidin‐inspired 7‐deazahypoxanthines as promising anticancer agents. Abstract : Expanding marine bounty : Analogues of marine alkaloid rigidins, based on the 7‐deazahypoxanthine skeleton, are available in one‐ or two‐step synthetic sequences and exert cytotoxicity by disrupting microtubule dynamics in cancer cells. In this work we extended the available SAR data to N3‐ and N9‐substituted derivatives. Furthermore, multidrug‐resistance proteins do not confer resistance to both N9‐unsubstituted and ‐substituted compounds. These results provide further impetus to investigate the rigidin‐inspired 7‐deazahypoxanthines as promising anticancer agents. … (more)
- Is Part Of:
- ChemMedChem. Volume 14:Number 3(2019)
- Journal:
- ChemMedChem
- Issue:
- Volume 14:Number 3(2019)
- Issue Display:
- Volume 14, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 14
- Issue:
- 3
- Issue Sort Value:
- 2019-0014-0003-0000
- Page Start:
- 322
- Page End:
- 333
- Publication Date:
- 2019-01-25
- Subjects:
- 7-deazapurines -- alkaloids -- antitumor agents -- drug discovery -- pyrrolo[2, 3-d]pyrimidines
Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1860-7187 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/110485305 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cmdc.201800658 ↗
- Languages:
- English
- ISSNs:
- 1860-7179
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3172.254000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 9494.xml